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Short Period Incidence Study of Severe Acute Respiratory Infection 
Year 1 rapid data from 2015-16
Seasonal and pandemic severe acute respiratory infections 
(SARI) are major public health threats. Globally, there are 
large knowledge gaps regarding presentation, cause, 
treatment and clinical outcomes for critically ill patients with 
SARI. The capability to initiate coordinated global 
observational studies to gather this data during a pandemic is 
very limited, requiring prior approvals and staff preparation. 
Our aims are to establish a research response capability to 
investigate descriptive epidemiology and infectious profiles of 
SARI through an ongoing global observational study. 
We report the preliminary results of our first annual SARI 
observational study. Protocol and case report forms were 
created through consensus of representatives from global 
clinical trials groups and using a standardized case-definition of 
SARI. Data were collected over a 7-day period during peak 
SARI seasons in respective global regions and entered into a 
central database. We report recruitment of patients across 5 
continents. Data were collected in critical care units where 
available, or equivalent where resource limitations prohibited 
specialty units. Data collection was structured in a “tiered” 
fashion - centres could tailor the intensity of data collection to 
their needs and capabilities (Table 1)
Through a Short PeRiod IncideNce sTudy of Severe Acute 
Respiratory Infection (SPRINT-SARI), we are creating a 
sustainable infrastructure for real-time data collection to 
better describe hospitalized and critically ill patients with SARI. 
It is feasible to rapidly and accurately collect standardised 
data describing patient demographics, hospital course, 
diagnoses, and outcomes for diverse patient populations. 
• There is heterogeneity of demographics, microbiology, and 
outcome among critically ill patients with SARI, with the 
majority of patients having no microbiologic diagnosis. 
• This infrastructure can be test-activated by networks and 
sites to maintain readiness between outbreaks, and can be 
activated for data collection at the participating sites during 
a pandemic and fill vital gaps in knowledge. Improvements 
in scale and data quality, accuracy of denominator 
projections, and applicability to diverse clinical contexts are 
underway.
• Further analyses of existing data will incorporate sites with 
more advanced data capabilities, including co-morbidities 
and other epidemiologic factors to better understand global 
mortality patterns from SARI. 
The SPRINT-SARI team would like to acknowledge the efforts of all local 
site investigators for collecting and sharing data. 
Anonymized data provided from networks conducting audit and/or 
research with local and national Ethics committee/Institutional Review 
Board approval. Data is shared with due respect to local and international 
Data Protection Legislation
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Table 1: Tiered data collection Figure 2: Mortality from SARI by continent, age, and pathogen
Srinivas Murthy*, for the SPRINT-SARI 
Investigators**
DATA	COLECTED Tier	0 Tier	1 Tier	2 Tier	3
Inclusion	Criteria ✔ ✔ ✔ ✔
Demographics;	Onset	and	Admission	 ✔ ✔ ✔
Op
tio
na
l
Treatment;	Outcome ✔ ✔ ✔
Infectious	Respiratory	Diagnosis	 ✔ ✔ ✔
Co-Morbidities;	Signs	and	Symptoms	 ✔ ✔
Complications;	Pathogen	Testing ✔ ✔
Medication ✔ ✔
Travel	History Additional	Info	
(Optional)Animal	Exposures
Treatment;	Lab	Results:	Day	1	 DAILY
Treatment;	Lab	Results:	Day	2	 DAILY DAILY
Epidemiology ✔ ✔
We report Tier 0 data from the 2015-16 season here.
BACKGROUND
METHODS
RESULTS CONCLUSIONS
N	=	229	
subjects
47	sites	
13	countries
Male:	55%
Female:	45%
Subjects	<	10	yrs:
26	(11	%)
Mechanical	
ventilation	
during	ICU	stay:	
n=75	(32.9%)
Median	age:	61
(IQR	39-74)
Figure 1: Demographic data
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